Person · CIK 1738048

Venrock Healthcare Capital Partners III

10% owner at Lycia Therapeutics, KalVista Pharmaceuticals and Oruka Therapeutics

Earlier: Tricida, VistaGen Therapeutics, Altimmune, Unum Therapeutics, Constellation Pharmaceuticals and Bellerophon Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$22.1M

Noticed on Form 144$0

Bought on Form 4$144.5M

Companies9

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Lycia Therapeutics LYCA	Common Stock	By Funds	6,850,237	Oct 30, 2026 · Filing · EDGAR
KalVista Pharmaceuticals KALV	Common Stock	By Funds	5,089,354	Mar 26, 2026 · Filing · EDGAR
KalVista Pharmaceuticals KALV	Pre-Funded Warrants (Right to Buy) exercise $0.00, into Common Stock	By Funds	655,738	Jan 30, 2025 · Filing · EDGAR
Oruka Therapeutics ORKA	Common Stock	By Funds	4,148,428	Feb 14, 2025 · Filing · EDGAR
Oruka Therapeutics ORKA	Pre-Funded Warrants (Right to Buy) exercise $0.00, into Common Stock	By Funds	300,000	Feb 10, 2025 · Filing · EDGAR
Oruka Therapeutics ORKA	Pre-Funded Warrants (Right to Buy) exercise $0.01, into Common Stock	By Funds	224,543	Feb 10, 2025 · Filing · EDGAR
Tricida	Common Stock	By Funds	3,751,406	Oct 26, 2022 · Filing · EDGAR
VistaGen Therapeutics	Common Stock	By Funds	20,637,286	Jul 12, 2022 · Filing · EDGAR
Altimmune	Common Stock	By Funds	3,500,000	Feb 25, 2021 · Filing · EDGAR
Altimmune	Warrant exercise $0.00, into Common Stock	By Funds	1,000,000	Feb 25, 2021 · Filing · EDGAR
Unum Therapeutics	Common Stock	By funds	4,355,273	Aug 18, 2020 · Filing · EDGAR
Unum Therapeutics	Series A Non-Voting Convertible Preferred Stock into Common Stock	By funds	13,636,000	Aug 13, 2020 · Filing · EDGAR
Constellation Pharmaceuticals	Common Stock	By Funds	4,016,873	Dec 13, 2019 · Filing · EDGAR
Bellerophon Therapeutics	Common Stock	By funds	6,435,173	Oct 28, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2026	—	—	$38.3M
Q1 2026	$3.7M	—	—
Q2 2025	—	—	$236K
Q1 2025	—	—	$4.5M
Q1 2024	—	—	$9.6M
Q4 2023	—	—	$6.5M
Q4 2022	$3.5M	Not machine-readable	$13.1M
Q3 2022	$53K	Not machine-readable	$19.4M
Q2 2022	—	—	$14.2M
Q3 2020	—	—	$1.1M
Q2 2020	—	—	$22.7M
Q4 2019	$525K	Not machine-readable	$13.8M
Q1 2019	$14.4M	Not machine-readable	$100K
Q3 2018	—	—	$949K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

No Form 144 notices with structured data (filed on EDGAR since April 2023).

Notice date	Noticed	Planned sale	Outcome	Links
Sales without a matching Form 144 · 13 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice KalVista Pharmaceuticals (KALV): Sold 3,183 at $19.12 on Mar 26, 2026 · $61K	Filing · EDGAR
—	—	—	Sold without notice KalVista Pharmaceuticals (KALV): Sold 15,417 at $18.82 on Mar 26, 2026 · $290K	Filing · EDGAR
—	—	—	Sold without notice KalVista Pharmaceuticals (KALV): Sold 21,386 at $17.76 on Mar 26, 2026 · $380K	Filing · EDGAR
—	—	—	Sold without notice KalVista Pharmaceuticals (KALV): Sold 160 at $17.53 on Mar 25, 2026 · $3K	Filing · EDGAR
—	—	—	Sold without notice KalVista Pharmaceuticals (KALV): Sold 174,485 at $16.95 on Mar 25, 2026 · $3M	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 2,367,174 at $0.46 on Oct 26, 2022 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 1,970,418 at $0.57 on Oct 25, 2022 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Tricida: Sold 2,113,948 at $0.61 on Oct 24, 2022 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable VistaGen Therapeutics: Sold 60,000 at $0.89 on Jul 12, 2022 · $53K	Filing · EDGAR
—	—	—	Notice not machine-readable Bellerophon Therapeutics: Sold 333,010 at $0.44 on Oct 28, 2019 · $146K	Filing · EDGAR
—	—	—	Notice not machine-readable Bellerophon Therapeutics: Sold 56,242 at $0.45 on Oct 25, 2019 · $26K	Filing · EDGAR
—	—	—	Notice not machine-readable Bellerophon Therapeutics: Sold 704,595 at $0.50 on Oct 24, 2019 · $353K	Filing · EDGAR
—	—	—	Notice not machine-readable KalVista Pharmaceuticals (KALV): Sold 500,000 at $28.75 on Mar 18, 2019 · $14.4M	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Lycia Therapeutics LYCA 10% owner · filings 2026 to 2026 · bought $38.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 30, 2026	Open-market or private purchase	+8,804	$26.27	$231K	6,850,037 By Funds	Filing · EDGAR
Oct 30, 2026	Open-market or private purchase	+200	$26.86	$5K	6,850,237 By Funds	Filing · EDGAR
Oct 29, 2026	Open-market or private purchase	+1,000	$26.33	$26K	6,841,233 By Funds	Filing · EDGAR
Oct 28, 2026	Open-market or private purchase	+10,570	$25.23	$267K	6,835,803 By Funds	Filing · EDGAR
Oct 28, 2026	Open-market or private purchase	+4,430	$25.97	$115K	6,840,233 By Funds	Filing · EDGAR
Oct 27, 2026	Open-market or private purchase	+8,729	$25.84	$226K	6,794,166 By Funds	Filing · EDGAR
Oct 27, 2026	Open-market or private purchase	+31,067	$26.84	$834K	6,825,233 By Funds	Filing · EDGAR
Oct 26, 2026	Derivative converted	+4,779,793			4,832,732 By Funds	Filing · EDGAR
Oct 26, 2026	Open-market or private purchase	+1,944,444	$18.00	$35M	6,777,176 By Funds	Filing · EDGAR
Oct 26, 2026	Open-market or private purchase	+8,261	$26.97	$223K	6,785,437 By Funds	Filing · EDGAR
Oct 26, 2026	Derivative converted Series C Preferred Stock	−17,142,578			0 By Funds	Filing · EDGAR
Oct 26, 2026	Derivative converted Series D Preferred Stock	−4,408,091			0 By Funds	Filing · EDGAR
Oct 23, 2026	Open-market or private purchase	+24,560	$25.68	$631K	24,560 By Funds	Filing · EDGAR
Oct 23, 2026	Open-market or private purchase	+28,379	$26.11	$741K	52,939 By Funds	Filing · EDGAR

KalVista Pharmaceuticals KALV 10% owner · filings 2018 to 2026 · sold $18.1M · bought $19.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 26, 2026	Open-market or private sale	−21,386	$17.76	$380K	5,107,954 By Funds	Filing · EDGAR
Mar 26, 2026	Open-market or private sale	−15,417	$18.82	$290K	5,092,537 By Funds	Filing · EDGAR
Mar 26, 2026	Open-market or private sale	−3,183	$19.12	$61K	5,089,354 By Funds	Filing · EDGAR
Mar 25, 2026	Open-market or private sale	−174,485	$16.95	$3M	5,129,500 By Funds	Filing · EDGAR
Mar 25, 2026	Open-market or private sale	−160	$17.53	$3K	5,129,340 By Funds	Filing · EDGAR
Apr 9, 2025	Open-market or private purchase	+25,000	$9.42	$236K	5,303,985 By Funds	Filing · EDGAR
Feb 13, 2025	Open-market or private purchase	+61,700	$9.33	$576K	5,278,985 By Funds	Filing · EDGAR
Feb 12, 2025	Open-market or private purchase	+100,000	$9.23	$923K	5,217,285 By Funds	Filing · EDGAR
Feb 11, 2025	Open-market or private purchase	+26,703	$9.18	$245K	5,117,285 By Funds	Filing · EDGAR
Feb 10, 2025	Open-market or private purchase	+4,137	$9.14	$38K	5,090,582 By Funds	Filing · EDGAR
Feb 7, 2025	Open-market or private purchase	+73,649	$9.29	$684K	5,086,445 By Funds	Filing · EDGAR
Feb 3, 2025	Open-market or private purchase	+14,562	$9.22	$134K	5,012,796 By Funds	Filing · EDGAR
Jan 31, 2025	Open-market or private purchase	+11,754	$8.89	$104K	4,998,234 By Funds	Filing · EDGAR
Jan 30, 2025	Open-market or private purchase	+43,707	$8.76	$383K	4,986,480 By Funds	Filing · EDGAR
Feb 20, 2024	Open-market or private purchase Pre-Funded Warrants (Right to Buy)	+655,738	$15.25	$10M	655,738 By Funds	Filing · EDGAR
Feb 8, 2024	Open-market or private purchase	+29,747	$14.70	$437K	4,824,731 By Funds	Filing · EDGAR
Feb 7, 2024	Open-market or private purchase	+51,827	$14.56	$755K	4,794,984 By Funds	Filing · EDGAR
Feb 6, 2024	Open-market or private purchase	+4,474	$14.74	$66K	4,743,157 By Funds	Filing · EDGAR
Jan 30, 2024	Open-market or private purchase	+88,099	$14.47	$1.3M	4,738,683 By Funds	Filing · EDGAR
Jan 29, 2024	Open-market or private purchase	+80,600	$14.22	$1.1M	4,650,584 By Funds	Filing · EDGAR
Jan 26, 2024	Open-market or private purchase	+4,174	$12.98	$54K	4,569,984 By Funds	Filing · EDGAR
Jan 25, 2024	Open-market or private purchase	+7,030	$12.73	$89K	4,565,810 By Funds	Filing · EDGAR
Jan 24, 2024	Open-market or private purchase	+20,686	$12.44	$257K	4,558,780 By Funds	Filing · EDGAR
Jan 23, 2024	Open-market or private purchase	+10,897	$12.54	$137K	4,538,094 By Funds	Filing · EDGAR
Jan 22, 2024	Open-market or private purchase	+67,546	$12.55	$848K	4,527,197 By Funds	Filing · EDGAR
Jan 19, 2024	Open-market or private purchase	+25,000	$12.43	$311K	4,459,651 By Funds	Filing · EDGAR
Jan 18, 2024	Open-market or private purchase	+39,680	$12.51	$496K	4,434,651 By Funds	Filing · EDGAR
Jan 17, 2024	Open-market or private purchase	+78,925	$12.60	$994K	4,394,971 By Funds	Filing · EDGAR
Jan 16, 2024	Open-market or private purchase	+19,599	$12.73	$249K	4,316,046 By Funds	Filing · EDGAR
Jan 11, 2024	Open-market or private purchase	+6,647	$12.68	$84K	4,296,447 By Funds	Filing · EDGAR
Jan 10, 2024	Open-market or private purchase	+47,700	$12.67	$604K	4,289,800 By Funds	Filing · EDGAR
Jan 9, 2024	Open-market or private purchase	+20,816	$12.56	$261K	4,242,100 By Funds	Filing · EDGAR
Jan 8, 2024	Open-market or private purchase	+69,184	$12.44	$861K	4,221,284 By Funds	Filing · EDGAR
Jan 4, 2024	Open-market or private purchase	+41,764	$12.11	$506K	4,152,100 By Funds	Filing · EDGAR
Jan 3, 2024	Open-market or private purchase	+17,605	$12.20	$215K	4,110,336 By Funds	Filing · EDGAR
Dec 29, 2023	Open-market or private purchase	+6,013	$12.49	$75K	4,092,731 By Funds	Filing · EDGAR
Dec 28, 2023	Open-market or private purchase	+471,490	$12.50	$5.9M	4,086,718 By Funds	Filing · EDGAR
Dec 27, 2023	Open-market or private purchase	+41,514	$11.97	$497K	3,615,228 By Funds	Filing · EDGAR
Mar 18, 2019	Open-market or private sale	−500,000	$28.75	$14.4M	1,544,112 By Funds	Filing · EDGAR

Oruka Therapeutics ORKA 10% owner · filings 2025 to 2025 · bought $1.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 14, 2025	Open-market or private purchase	+88,794	$11.44	$1M	4,148,428 By Funds	Filing · EDGAR
Feb 13, 2025	Open-market or private purchase	+14,950	$11.63	$174K	4,059,634 By Funds	Filing · EDGAR
Feb 12, 2025	Open-market or private purchase	+8,971	$11.86	$106K	4,044,684 By Funds	Filing · EDGAR
Feb 11, 2025	Open-market or private purchase	+9,593	$10.95	$105K	4,035,713 By Funds	Filing · EDGAR
Feb 10, 2025	Open-market or private purchase	+574	$10.90	$6K	4,026,120 By Funds	Filing · EDGAR

Tricida 10% owner · filings 2022 to 2022 · sold $3.5M · bought $46.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 26, 2022	Open-market or private sale	−2,367,174	$0.46	$1.1M	3,751,406 By Funds	Filing · EDGAR
Oct 25, 2022	Open-market or private sale	−1,970,418	$0.57	$1.1M	6,118,580 By Funds	Filing · EDGAR
Oct 24, 2022	Open-market or private sale	−2,113,948	$0.61	$1.3M	8,088,998 By Funds	Filing · EDGAR
Oct 19, 2022	Open-market or private purchase	+241,366	$10.29	$2.5M	10,132,846 By Funds	Filing · EDGAR
Oct 19, 2022	Open-market or private purchase	+70,100	$11.25	$789K	10,202,946 By Funds	Filing · EDGAR
Oct 18, 2022	Open-market or private purchase	+40,400	$11.98	$484K	9,891,480 By Funds	Filing · EDGAR
Oct 17, 2022	Open-market or private purchase	+170,292	$11.67	$2M	9,851,080 By Funds	Filing · EDGAR
Oct 13, 2022	Open-market or private purchase	+4,674	$11.98	$56K	9,680,788 By Funds	Filing · EDGAR
Oct 11, 2022	Open-market or private purchase	+25,000	$11.85	$296K	9,676,114 By Funds	Filing · EDGAR
Oct 10, 2022	Open-market or private purchase	+80,314	$11.89	$955K	9,651,114 By Funds	Filing · EDGAR
Oct 7, 2022	Open-market or private purchase	+28,900	$12.00	$347K	9,570,800 By Funds	Filing · EDGAR
Oct 4, 2022	Open-market or private purchase	+223,100	$11.81	$2.6M	9,541,900 By Funds	Filing · EDGAR
Oct 3, 2022	Open-market or private purchase	+268,736	$11.27	$3M	9,318,800 By Funds	Filing · EDGAR
Sep 29, 2022	Open-market or private purchase	+168,187	$9.92	$1.7M	9,050,064 By Funds	Filing · EDGAR
Sep 28, 2022	Open-market or private purchase	+76,600	$9.92	$760K	8,881,877 By Funds	Filing · EDGAR
Sep 27, 2022	Open-market or private purchase	+115,000	$9.38	$1.1M	8,805,277 By Funds	Filing · EDGAR
Sep 26, 2022	Open-market or private purchase	+395,614	$8.56	$3.4M	8,690,277 By Funds	Filing · EDGAR
Sep 7, 2022	Open-market or private purchase	+473,459	$11.40	$5.4M	8,294,663 By Funds	Filing · EDGAR
Sep 6, 2022	Open-market or private purchase	+150,223	$11.43	$1.7M	7,821,204 By Funds	Filing · EDGAR
Sep 2, 2022	Open-market or private purchase	+63,030	$12.76	$804K	7,670,981 By Funds	Filing · EDGAR
Aug 30, 2022	Open-market or private purchase	+50,000	$12.20	$610K	7,607,951 By Funds	Filing · EDGAR
Jul 29, 2022	Open-market or private purchase	+18,900	$9.21	$174K	7,557,951 By Funds	Filing · EDGAR
Jul 25, 2022	Open-market or private purchase	+29,199	$8.95	$261K	7,539,051 By Funds	Filing · EDGAR
Jul 22, 2022	Open-market or private purchase	+15,000	$9.21	$138K	7,509,852 By Funds	Filing · EDGAR
Jul 21, 2022	Open-market or private purchase	+30,000	$9.59	$288K	7,494,852 By Funds	Filing · EDGAR
Jul 20, 2022	Open-market or private purchase	+25,000	$9.54	$238K	7,464,852 By Funds	Filing · EDGAR
Jul 19, 2022	Open-market or private purchase	+25,000	$9.47	$237K	7,439,852 By Funds	Filing · EDGAR
Jul 18, 2022	Open-market or private purchase	+100,000	$9.02	$902K	7,414,852 By Funds	Filing · EDGAR
Jul 14, 2022	Open-market or private purchase	+36,717	$9.85	$362K	7,314,852 By Funds	Filing · EDGAR
Jul 13, 2022	Open-market or private purchase	+32,856	$9.98	$328K	7,278,135 By Funds	Filing · EDGAR
Jul 12, 2022	Open-market or private purchase	+25,000	$9.81	$245K	7,245,279 By Funds	Filing · EDGAR
Jul 5, 2022	Open-market or private purchase	+32,500	$9.53	$310K	7,220,279 By Funds	Filing · EDGAR
Jul 1, 2022	Open-market or private purchase	+55,700	$9.65	$538K	7,187,779 By Funds	Filing · EDGAR
Jun 30, 2022	Open-market or private purchase	+11,958	$9.66	$116K	7,132,079 By Funds	Filing · EDGAR
Jun 29, 2022	Open-market or private purchase	+16,546	$9.93	$164K	7,120,121 By Funds	Filing · EDGAR
Jun 28, 2022	Open-market or private purchase	+34,366	$9.71	$334K	7,103,575 By Funds	Filing · EDGAR
Jun 24, 2022	Open-market or private purchase	+149,120	$9.68	$1.4M	7,069,209 By Funds	Filing · EDGAR
Jun 23, 2022	Open-market or private purchase	+200,000	$10.50	$2.1M	6,920,089 By Funds	Filing · EDGAR
Jun 22, 2022	Open-market or private purchase	+142,900	$10.90	$1.6M	6,720,089 By Funds	Filing · EDGAR
Jun 16, 2022	Open-market or private purchase	+5,951	$9.69	$58K	6,577,189 By funds	Filing · EDGAR
Jun 14, 2022	Open-market or private purchase	+10,000	$8.72	$87K	6,571,238 By Funds	Filing · EDGAR
Jun 13, 2022	Open-market or private purchase	+50,000	$8.14	$407K	6,561,238 By Funds	Filing · EDGAR
Jun 10, 2022	Open-market or private purchase	+58,054	$8.91	$517K	6,511,238 By Funds	Filing · EDGAR
Jun 9, 2022	Open-market or private purchase	+109,100	$8.97	$979K	6,453,184 By Funds	Filing · EDGAR
Jun 8, 2022	Open-market or private purchase	+111,111	$9.51	$1.1M	6,344,084 By Funds	Filing · EDGAR
Jun 7, 2022	Open-market or private purchase	+367,813	$9.89	$3.6M	6,232,973 By Funds	Filing · EDGAR
Jun 6, 2022	Open-market or private purchase	+91,506	$9.35	$856K	5,865,160 By Funds	Filing · EDGAR
Jun 3, 2022	Open-market or private purchase	+37,643	$9.33	$351K	5,773,654 By Funds	Filing · EDGAR
Jun 2, 2022	Open-market or private purchase	+61,722	$8.78	$542K	5,736,011 By Funds	Filing · EDGAR

VistaGen Therapeutics 10% owner · filings 2022 to 2022 · sold $53K

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 12, 2022	Open-market or private sale	−60,000	$0.89	$53K	20,637,286 By Funds	Filing · EDGAR

Altimmune 10% owner · filings 2020 to 2021 · bought $22.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 25, 2021	Other acquisition or disposition (see the filing)	−1,000,000	$0.00	$100	3,500,000 By Funds	Filing · EDGAR
Feb 25, 2021	Other acquisition or disposition (see the filing) Warrant	+1,000,000			1,000,000 By Funds	Filing · EDGAR
Jun 15, 2020	Open-market or private purchase	+1,500,000	$7.54	$11.3M	4,500,000 By Funds	Filing · EDGAR
May 28, 2020	Open-market or private purchase	+27,763	$7.79	$216K	2,826,289 By Funds	Filing · EDGAR
May 28, 2020	Open-market or private purchase	+173,711	$8.87	$1.5M	3,000,000 By Funds	Filing · EDGAR
May 27, 2020	Open-market or private purchase	+125,162	$7.23	$905K	2,521,526 By Funds	Filing · EDGAR
May 27, 2020	Open-market or private purchase	+277,000	$7.92	$2.2M	2,798,526 By Funds	Filing · EDGAR
May 26, 2020	Open-market or private purchase	+309,453	$8.79	$2.7M	2,005,817 By Funds	Filing · EDGAR
May 26, 2020	Open-market or private purchase	+390,547	$9.78	$3.8M	2,396,364 By Funds	Filing · EDGAR

Unum Therapeutics 10% owner · filings 2020 to 2020 · bought $1.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 18, 2020	Open-market or private purchase	+101,000	$2.62	$265K	4,355,273 By funds	Filing · EDGAR
Aug 17, 2020	Open-market or private purchase	+250,000	$2.57	$643K	4,254,273 By funds	Filing · EDGAR
Aug 14, 2020	Open-market or private purchase	+100,000	$2.30	$230K	4,004,273 By funds	Filing · EDGAR

Constellation Pharmaceuticals 10% owner · filings 2019 to 2019 · bought $13.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 13, 2019	Open-market or private purchase	+400,000	$34.50	$13.8M	4,016,873 By Funds	Filing · EDGAR

Bellerophon Therapeutics 10% owner · filings 2018 to 2019 · sold $525K · bought $1M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 28, 2019	Open-market or private sale	−333,010	$0.44	$146K	6,435,173 By funds	Filing · EDGAR
Oct 25, 2019	Open-market or private sale	−56,242	$0.45	$26K	6,768,183 By funds	Filing · EDGAR
Oct 24, 2019	Open-market or private sale	−704,595	$0.50	$353K	6,824,425 By funds	Filing · EDGAR
Jan 23, 2019	Open-market or private purchase	+142,857	$0.70	$100K	7,529,020 By funds	Filing · EDGAR
Sep 17, 2018	Open-market or private purchase	+60,000	$1.18	$71K	7,386,163 By funds	Filing · EDGAR
Sep 14, 2018	Open-market or private purchase	+75,000	$1.23	$92K	7,326,163 By funds	Filing · EDGAR
Sep 13, 2018	Open-market or private purchase	+75,000	$1.19	$89K	7,251,163 By funds	Filing · EDGAR
Sep 12, 2018	Open-market or private purchase	+75,000	$1.15	$86K	7,176,163 By funds	Filing · EDGAR
Sep 11, 2018	Open-market or private purchase	+200,000	$1.14	$229K	7,101,163 By funds	Filing · EDGAR
Sep 10, 2018	Open-market or private purchase	+200,000	$1.22	$244K	6,901,163 By funds	Filing · EDGAR
Sep 7, 2018	Open-market or private purchase	+60,000	$0.90	$54K	6,701,163 By funds	Filing · EDGAR
Sep 6, 2018	Open-market or private purchase	+50,000	$0.84	$42K	6,641,163 By funds	Filing · EDGAR
Sep 5, 2018	Open-market or private purchase	+50,000	$0.85	$42K	6,591,163 By funds	Filing · EDGAR

All 60 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Oct 30, 2026	Form 4	Lycia Therapeutics LYCA	Filing · EDGAR
Oct 27, 2026	Form 4	Lycia Therapeutics LYCA	Filing · EDGAR
Oct 22, 2026	Form 3	Lycia Therapeutics LYCA	Filing · EDGAR
Mar 27, 2026	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Apr 11, 2025	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 27, 2025	Form 4	Oruka Therapeutics ORKA	Filing · EDGAR
Feb 27, 2025	Form 3	Oruka Therapeutics ORKA	Filing · EDGAR
Feb 14, 2025	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 11, 2025	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 3, 2025	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 3, 2025	Form 3	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 22, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 8, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Feb 1, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Jan 29, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Jan 24, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Jan 19, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Jan 16, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Jan 10, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Jan 5, 2024	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Dec 29, 2023	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Dec 28, 2023	Form 3	KalVista Pharmaceuticals KALV	Filing · EDGAR
Oct 26, 2022	Form 4	Tricida	Filing · EDGAR
Oct 20, 2022	Form 4	Tricida	Filing · EDGAR
Oct 17, 2022	Form 4	Tricida	Filing · EDGAR
Oct 11, 2022	Form 4	Tricida	Filing · EDGAR
Oct 6, 2022	Form 4	Tricida	Filing · EDGAR
Oct 3, 2022	Form 4	Tricida	Filing · EDGAR
Sep 28, 2022	Form 4	Tricida	Filing · EDGAR
Sep 7, 2022	Form 4	Tricida	Filing · EDGAR
Sep 1, 2022	Form 4	Tricida	Filing · EDGAR
Aug 2, 2022	Form 4	Tricida	Filing · EDGAR
Jul 25, 2022	Form 4	Tricida	Filing · EDGAR
Jul 20, 2022	Form 4	Tricida	Filing · EDGAR
Jul 14, 2022	Form 4	Tricida	Filing · EDGAR
Jul 14, 2022	Form 4	VistaGen Therapeutics	Filing · EDGAR
Jul 8, 2022	Form 3	VistaGen Therapeutics	Filing · EDGAR
Jul 6, 2022	Form 4	Tricida	Filing · EDGAR
Jun 30, 2022	Form 4	Tricida	Filing · EDGAR
Jun 24, 2022	Form 4	Tricida	Filing · EDGAR
Jun 21, 2022	Form 4	Tricida	Filing · EDGAR
Jun 14, 2022	Form 4	Tricida	Filing · EDGAR
Jun 9, 2022	Form 4	Tricida	Filing · EDGAR
Jun 6, 2022	Form 4	Tricida	Filing · EDGAR
Jun 6, 2022	Form 3	Tricida	Filing · EDGAR
Mar 1, 2021	Form 4	Altimmune	Filing · EDGAR
Aug 18, 2020	Form 4	Unum Therapeutics	Filing · EDGAR
Aug 18, 2020	Form 3	Unum Therapeutics	Filing · EDGAR
Jun 15, 2020	Form 4	Altimmune	Filing · EDGAR
May 28, 2020	Form 4	Altimmune	Filing · EDGAR
May 28, 2020	Form 3	Altimmune	Filing · EDGAR
Dec 16, 2019	Form 4	Constellation Pharmaceuticals	Filing · EDGAR
Oct 28, 2019	Form 4	Bellerophon Therapeutics	Filing · EDGAR
Oct 4, 2019	Form 3	Constellation Pharmaceuticals	Filing · EDGAR
Mar 20, 2019	Form 4	KalVista Pharmaceuticals KALV	Filing · EDGAR
Mar 14, 2019	Form 4	Bellerophon Therapeutics	Filing · EDGAR
Sep 17, 2018	Form 4	Bellerophon Therapeutics	Filing · EDGAR
Sep 12, 2018	Form 4	Bellerophon Therapeutics	Filing · EDGAR
Sep 10, 2018	Form 3	KalVista Pharmaceuticals KALV	Filing · EDGAR
Sep 7, 2018	Form 4	Bellerophon Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.